Intriguingly, PARP inhibitors (PARPi) are commonly used as maintenance therapy in HGSOC patients with homologous recombination defects [28–30], and studies conducted in other cancer types suggested that FOXM1 inhibitors synergize with this class of drugs [31, 32], thanks to the reduced expression of homologous recombination-related genes which are among FOXM1 targets. This evidence concerns the gene FOXM1 and cancer.